Investing.com - Abbott Labs (NYSE: ABT) reported first quarter EPS of $0.98, $0.02 better than the analyst estimate of $0.96. Revenue for the quarter came in at $9.96B versus the consensus estimate of $9.89B.
Guidance
Abbott Labs sees Q2 2024 EPS of $1.08-$1.12 versus the analyst consensus of $1.12.
Abbott Labs sees FY 2024 EPS of $4.55-$4.70 versus the analyst consensus of $4.59.
Abbott Labs's stock price closed at $109.20. It is down -4.79% in the last 3 months and up 4.85% in the last 12 months.
Abbott Labs saw 5 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Abbott Labs's stock price’s past reactions to earnings here.
According to InvestingPro, Abbott Labs's Financial Health score is "good performance".
Check out Abbott Labs's recent earnings performance, and Abbott Labs's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar